Literature DB >> 19654064

Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.

Langzhou Song1, Yi Zhang, Nadezhda E Yun, Allison L Poussard, Jeanon N Smith, Jennifer K Smith, Viktoriya Borisevich, Jenna J Linde, Michele A Zacks, Hong Li, Uma Kavita, Lucia Reiserova, Xiangyu Liu, Kunmi Dumuren, Bhuvaneswari Balasubramanian, Bruce Weaver, Jason Parent, Scott Umlauf, Ge Liu, Jim Huleatt, Lynda Tussey, Slobodan Paessler.   

Abstract

Transmission of highly pathogenic avian influenza (HPAI) between birds and humans is an ongoing threat that holds potential for the emergence of a pandemic influenza strain. A major barrier to an effective vaccine against avian influenza has been the generally poor immunopotency of many of the HPAI strains coupled with the manufacturing constraints employing conventional methodologies. Fusion of flagellin, a toll-like receptor-5 ligand, to vaccine antigens has been shown to enhance the immune response to the fused antigen in preclinical studies. Here, we have evaluated the immunogenicity and efficacy of a panel of flagellin-based hemagglutinin (HA) globular head fusion vaccines in inbred mice. The HA globular head of these vaccines is derived from the A/Vietnam/1203/04 (VN04; H5N1) HA molecule. We find that replacement of domain D3 of flagellin with the VN04 HA globular head creates a highly effective vaccine that elicits protective HAI titers which protect mice against disease and death in a lethal challenge model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654064      PMCID: PMC3571653          DOI: 10.1016/j.vaccine.2009.07.060

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  Avian influenza. Wild birds only partly to blame in spreading H5N1.

Authors:  Dennis Normile
Journal:  Science       Date:  2006-06-09       Impact factor: 47.728

2.  Ferrets and the challenges of H5N1 vaccine formulation.

Authors:  Alan W Hampson
Journal:  J Infect Dis       Date:  2006-06-09       Impact factor: 5.226

Review 3.  Towards an epitope-based human vaccine for influenza.

Authors:  Tamar Ben-Yedidia; Ruth Arnon
Journal:  Hum Vaccin       Date:  2005-05-15

4.  Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.

Authors:  James W Huleatt; Andrea R Jacobs; Jie Tang; Priyanka Desai; Elizabeth B Kopp; Yan Huang; Langzhou Song; Valerian Nakaar; T J Powell
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

5.  A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.

Authors:  William F McDonald; James W Huleatt; Harald G Foellmer; Duane Hewitt; Jie Tang; Priyanka Desai; Albert Price; Andrea Jacobs; Virginia N Takahashi; Yan Huang; Valerian Nakaar; Lena Alexopoulou; Erol Fikrig; T J Powell
Journal:  J Infect Dis       Date:  2007-04-17       Impact factor: 5.226

Review 6.  The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-03-20       Impact factor: 3.402

Review 7.  Avian and pandemic influenza: an overview.

Authors:  Gregory A Poland; Robert M Jacobson; Paul V Targonski
Journal:  Vaccine       Date:  2007-01-18       Impact factor: 3.641

Review 8.  Epitope-based vaccine against influenza.

Authors:  Tamar Ben-Yedidia; Ruth Arnon
Journal:  Expert Rev Vaccines       Date:  2007-12       Impact factor: 5.217

9.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.

Authors:  James W Huleatt; Valerian Nakaar; Priyanka Desai; Yan Huang; Duane Hewitt; Andrea Jacobs; Jie Tang; William McDonald; Langzhou Song; Robert K Evans; Scott Umlauf; Lynda Tussey; T J Powell
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

10.  Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Authors:  Rick A Bright; Donald M Carter; Corey J Crevar; Franklin R Toapanta; Jonathan D Steckbeck; Kelly S Cole; Niranjan M Kumar; Peter Pushko; Gale Smith; Terrence M Tumpey; Ted M Ross
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

View more
  32 in total

Review 1.  Flagellin as an adjuvant: cellular mechanisms and potential.

Authors:  Steven B Mizel; John T Bates
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

Review 2.  Reevaluating the hype: four bacterial metabolites under scrutiny.

Authors:  E E Fröhlich; R Mayerhofer; P Holzer
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

3.  Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization.

Authors:  Jingyi Yang; Maohua Zhong; Yan Zhang; Ejuan Zhang; Ying Sun; Yuan Cao; Yaoming Li; Dihan Zhou; Benxia He; Yaoqing Chen; Yi Yang; Jie Yu; Huimin Yan
Journal:  Hum Vaccin Immunother       Date:  2013-02-01       Impact factor: 3.452

Review 4.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

5.  Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Authors:  Kirill Kalnin; Timothy Tibbitts; Yanhua Yan; Svetlana Stegalkina; Lihua Shen; Victor Costa; Robert Sabharwal; Stephen F Anderson; Patricia M Day; Neil Christensen; John T Schiller; Subhashini Jagu; Richard B S Roden; Jeffrey Almond; Harold Kleanthous
Journal:  Vaccine       Date:  2014-04-26       Impact factor: 3.641

6.  The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure.

Authors:  Rebecca M DuBois; José Manuel Aguilar-Yañez; Gonzalo I Mendoza-Ochoa; Yuriana Oropeza-Almazán; Stacey Schultz-Cherry; Mario Moisés Alvarez; Stephen W White; Charles J Russell
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

7.  Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.

Authors:  Ge Liu; Langzhou Song; David W C Beasley; Robert Putnak; Jason Parent; John Misczak; Hong Li; Lucia Reiserova; Xiangyu Liu; Haijun Tian; Wenzhe Liu; Darlene Labonte; Lihua Duan; Youngsun Kim; Linda Travalent; Devin Wigington; Bruce Weaver; Lynda Tussey
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

8.  Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing pauci-mannose, high-mannose, or complex type N-glycans.

Authors:  Shih-Chang Lin; Jia-Tsrong Jan; Ben Dionne; Michael Butler; Ming-Hsi Huang; Chung-Yi Wu; Chi-Huey Wong; Suh-Chin Wu
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

9.  Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice.

Authors:  Ge Liu; Bart Tarbet; Langzhou Song; Lucia Reiserova; Bruce Weaver; Yan Chen; Hong Li; Fu Hou; Xiangyu Liu; Jason Parent; Scott Umlauf; Alan Shaw; Lynda Tussey
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240

10.  A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.

Authors:  Anthony E Gregory; Barbara M Judy; Omar Qazi; Carla A Blumentritt; Katherine A Brown; Andrew M Shaw; Alfredo G Torres; Richard W Titball
Journal:  Nanomedicine       Date:  2014-09-03       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.